REDWOOD CITY, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its first U.S. patent on its MAbTrap™ antibody display technology, one of the company's novel antibody platform technologies. OncoMed's MAbTrap™ technology enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.
The new patent, U.S. Patent No. 8,551,715, relates to methods of producing libraries of cells that express membrane-bound antibodies or other specific binding agents on their surface, and methods of identifying the cells in such libraries that express an antibody or other agent having the desired binding characteristics. The patented methods include novel mammalian cell display methods. Related patent applications are currently pending in the U.S., Europe, Japan, China, and a number of other countries worldwide. The new patent and related applications are all solely owned by OncoMed.
"The MAbTrap™ technology was invented and developed at OncoMed and provides a versatile platform for creating next-generation antibodies with highly-tailored attributes," said Austin Gurney, Ph.D., OncoMed's Senior Vice President of Molecular and Cellular Biology. MAbTrap™ allows for the screening of large libraries of antibodies using mammalian or other cells for monoclonal antibody discovery and optimization. OncoMed's proprietary antibody platform technologies also include bispecific antibody technologies and hybridoma technologies."Our patented MAbTrap™ antibody display technology is an innovative and powerful tool for the discovery and optimization of antibodies," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed. "We have already successfully used MAbTrap™ to identify promising new product candidates and expect this technology to continue to play an important role in our future efforts to identify and develop new generations of anti-cancer stem cell agents."